Patents by Inventor Arne Mork

Arne Mork has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160083359
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 24, 2016
    Inventors: Benny Bang-Andersen, André Faldt, Arne Mørk, Heidi Lopez De Diego, René Holm, Tine Bryan Stensbøl, Lone Munch Ringgard, Michael J. Mealy, Michael Harold Rock, Jørgen Brodersen, Morten Jørgensen, Nicholas Moore
  • Patent number: 9125909
    Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol
  • Patent number: 9125910
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt
  • Patent number: 9125908
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • Publication number: 20150005318
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Application
    Filed: September 9, 2014
    Publication date: January 1, 2015
    Inventors: Benny Bang-Andersen, Arne Mork, Nicholas Moore, Tine Bryan Stensbol
  • Publication number: 20140377363
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: Benny Bang-Andersen, Arne Mork, Nicholas Moore, Tine Bryan Stensbol
  • Publication number: 20140315921
    Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
    Type: Application
    Filed: July 9, 2014
    Publication date: October 23, 2014
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol, Nicholas Moore
  • Publication number: 20140248355
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: April 1, 2014
    Publication date: September 4, 2014
    Applicant: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Nicholas Moore, Tine Bryan Stensbol
  • Publication number: 20140248356
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: April 1, 2014
    Publication date: September 4, 2014
    Applicant: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Nicholas Moore, Tine Bryan Stensbol
  • Patent number: 8722684
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: May 13, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol, Nicholas Moore
  • Publication number: 20100297240
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: June 15, 2007
    Publication date: November 25, 2010
    Applicant: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez De Diego, Rene Holm, Tine Bryan Stensbol, Lone Munch Ringgaard, Michael J. Mealy, Michael Harold Rock, Jorgen Brodersen, Morten Jorgensen, Nicholas Moore
  • Publication number: 20090176808
    Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.
    Type: Application
    Filed: March 18, 2009
    Publication date: July 9, 2009
    Applicant: H. Lundbeck A/S
    Inventors: Thomas Ivo Franciscus Hubert Cremers, Hakan Vilhelm Wikstrom, Johan Antonie Den Boer, Fokko Jan Bosker, Bernard Hendrik Cornelis Westerink, Klaus Peter Bogeso, Sandra Hogg, Arne Mork
  • Publication number: 20090054510
    Abstract: An assay for identifying compounds with increased efficacy in the treatment of depression is disclosed. The assay comprises the steps of determining whether a test compound inhibits SERT and whether it inhibits with an allosteric site ion SERT.
    Type: Application
    Filed: March 21, 2007
    Publication date: February 26, 2009
    Applicant: H. LUNDBECK A/S
    Inventors: Tine Bryan Stensbol, Arne Mork
  • Publication number: 20080004338
    Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.
    Type: Application
    Filed: September 12, 2007
    Publication date: January 3, 2008
    Applicant: H. LUNDBECK A/S
    Inventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
  • Publication number: 20070105843
    Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.
    Type: Application
    Filed: October 5, 2006
    Publication date: May 10, 2007
    Applicant: H. Lundbeck A/S
    Inventors: Thomas Cremers, Hakan Wikstrom, Johan Den Boer, Fokko Bosker, Bernard Westernik, Klaus Bogeso, Sandra Willigers, Arne Mork
  • Publication number: 20050288355
    Abstract: The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulsive control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.
    Type: Application
    Filed: June 19, 2003
    Publication date: December 29, 2005
    Inventors: Arne Mork, Thomas Cremers, Sandra Willigers
  • Publication number: 20040198810
    Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.
    Type: Application
    Filed: August 20, 2003
    Publication date: October 7, 2004
    Applicant: H. Lundbeck A/S
    Inventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
  • Publication number: 20040198809
    Abstract: The present invention relates to the use of enantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resitant” patients.
    Type: Application
    Filed: June 8, 2004
    Publication date: October 7, 2004
    Inventors: Connie Sanchez, Arne Mork
  • Publication number: 20040198811
    Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.
    Type: Application
    Filed: August 20, 2003
    Publication date: October 7, 2004
    Applicant: H. Lundbeck A/S
    Inventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
  • Publication number: 20040192764
    Abstract: The present invention relates to the use of an antiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.
    Type: Application
    Filed: August 20, 2003
    Publication date: September 30, 2004
    Applicant: H. Lundbeck A/S
    Inventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork